A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

NCT01035502 | Completed Phase 2

• 1 other identifier: CP4055-205
• Study Type: interventional
• Target: 51
• Locations: 4 countries
• Sites: 8

Brief Summary

The main objective of this study is to assess the biological activity of elacytarabine in combination with idarubicin in patients with acute myeloid leukaemia who has failed the first course of a remission-induction treatment with cytarabine (ara-C). In addition, the correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall survival will be studied.

Conditions

Acute Myeloid Leukemia

Keywords

Cancer; CP-4055; elacytarabine; combination; idarubicin; Acute myeloid leukaemia (AML)

Outcome Measures

Primary Outcomes (1)

• Determine the rate of complete remission (CR), including complete remission with incomplete blood count recovery (CRi) in patients with AML who have not attained blast clearance after the first course of a ara-C based remission-induction therapy.

  Day 21 in each course

Secondary Outcomes (4)

• Obtain indication on the independence between hENT1 expression level and CR or CRi. Obtain guidance on disease free survival (DFS). Obtain guidance on event free survival (EFS). Characterize the safety profile of elacytarabine plus idarubicin.

  Day 21 in each course

• Duration of disease free survival (DFS), defined as time from CR + CRi to relapse

  Study end

• Duration of event free survival (EFS), defined as time from day one of therapy until relapse or death from any cause

  Study end

• Characterize the safety profile of elacytarabine plus idarubicin in this patient population

  Study end

Study Arms (1)

Elacytarabine plus idarubicin

EXPERIMENTAL

Drug: Elacytarabine plus idarubicin

Interventions

Elacytarabine plus idarubicin DRUG

Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle. Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w. It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy.

Elacytarabine plus idarubicin

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with a confirmed diagnosis of AML according to WHO classification (excluding acute promyelocytic leukaemia)
• Patients who have received one previous standard dose ara-C-containing regimen aiming at induction of complete remission (CR) and who have more than 5 % remaining blast cells in bone marrow following the first course of remission-induction or by other means documented residual disease (i.e. circulating blasts, persistent chloromas, other evident disease from day 12 on).
• Patients from whom samples for determination of hENT1 status on leukemic blast cells can be taken and prepared at diagnosis and/or at baseline
• Patients must be 18 years of age or older
• Patients must have ECOG performance status (PS) of 0 - 2
• Left ventricular ejection fraction (LVEF) must be \>= 45 % as measured by MUGA scan or 2D ECHO within 14 days prior to start of therapy.
• Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to beginning treatment on this study
• Male and female patients must use acceptable contraceptive methods for the duration of time on study, and males also for 3 months after the last elacytarabine dose
• Patients must be capable of understanding and complying with parameters as outlined in the protocol, and able and willing to sign a written informed consent form
• Patients must have the following clinical laboratory values:
• Serum creatinine \<= 1.5 x the institutional upper limit of normal (ULN)
• Total bilirubin \<= 1.5 x the ULN according to national prescribing information unless considered due to Gilbert's syndrome
• Alanine aminotransferase (ALT) (SGPT), or aspartate aminotransferase (AST) (SGOT) \<= 2.5 x the ULN unless considered due to organ leukemic involvement
• Patients must be eligible for administration of idarubicin according to current national prescribing information for idarubicin

You may not qualify if:

• A history of allergic reactions to egg, idarubicin and/or other anthracyclines or other components of the products. A history of allergic reactions to ara-C of CTCAE grade 3 or 4
• Persistent clinically significant and relevant toxicities from the previous course of chemotherapy
• A cancer history, that according to the investigator might confound the assessment of the study endpoints
• Patients with prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 300 mg/m2 according to the following calculation index: X/300 + Y/160 \< 1 where X is the doxorubicin or equivalent dose in mg/m2 and Y is the mitoxantrone dose in mg/m2. These calculations are to be used as guidance as there is no maximum cumulative dose defined in the summary of product characteristics (SPC) for idarubicin. The patient should tolerate minimum one course of combination therapy
• Active heart disease including myocardial infarction within the previous 3 months, symptomatic coronary disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure. Any NYHA grade 3 or 4
• Known positive status for human immunodeficiency virus (HIV)
• Pregnant and nursing patients are excluded because the effects of elacytarabine on a fetus or a nursing child are unknown
• Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, or psychiatric illness/social situations that may reduce compliance with study requirements
• Patients receiving hydroxyurea within the last 12 hours prior to treatment on this protocol or any other investigational or standard cytotoxic treatment within the last 14 days, except the first remission-induction course
• Any medical condition, which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities

Sponsors & Collaborators

• Clavis Pharma: lead
• Theradex: collaborator
• Syneos Health: collaborator

Study Sites (8)

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

CHU Lyon, Hospital Edouard Herriot

Lyon, 69437, France

Location

Institut Paoli-Calmettes

Marseille, 13273, France

Location

CHU Toulouse, Hospital Purpan

Toulouse, 31059, France

Location

Charite University Hospital Benjamin Franklin

Berlin, 12200, Germany

Location

Universitätsklinikum Münster

Münster, Germany

Location

Universitätsklinikum Ulm

Ulm, D-89081, Germany

Location

Haukeland University Hospital

Bergen, Norway

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute; Neoplasms

Interventions

5'-oleoyl cytarabine; Idarubicin

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Daunorubicin; Anthracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates

Study Officials

• David A Rizzieri, MD

  Duke University Medical Center, Durham, NC, USA

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 15, 2009
• First Posted: December 18, 2009
• Study Start: December 1, 2009
• Primary Completion: May 1, 2013
• Study Completion: June 1, 2013
• Last Updated: September 27, 2013

Record last verified: 2013-09

Locations

US (1); DE (3); FR (3); NO (1)